Isis Pharmaceuticals, Inc. (ISIS) Posts Q2 Loss of 10c/Share

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) reported Q2 EPS of ($0.10), $0.02 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $57.1 million versus the consensus estimate of $45.6 million.

The company reported pro forma net operating income of $1.1 million and a pro forma net operating loss (NOL) of $21.5 million for the three and six months ended June 30, 2014, respectively, compared to an NOL of $5.3 million and $799,000 for the same periods in 2013.

For earnings history and earnings-related data on Isis Pharmaceuticals, Inc. (ISIS) click here.

You May Also Be Interested In

• Bank of America (BAC) Tops Q1 EPS by $0.07, Beats on Revenue
• Mercantile Bank (MBWM) Tops Q1 EPS by 20c
• Pacific Bio (PACB) says prelim. revenue for Q1 was below expectations due to customers delaying instrument purchases